2022 CDC Clinical Practice Guideline for Prescribing Opioids for Oral and Dental Pain

This course provides an overview of the 2022 CDC Guidelines for Prescribing Opioids and how they can be applied to treating oral and dental pain.

Target Audience

All Prescribers of Controlled Substances

MD/DO

Advanced Practice Clinicians

Registered Nurses

Learning Objectives

Examine opioid prescribing patterns among dentists and the association between prescribing rates, the development of an opioid use disorder, and opioid overdose deaths.

 Explain the disease of chronic pain, pain modulation, and the role of endogenous opioids and endorphins in pain and opioid use disorders.

 Delineate alternatives to opioid prescribing that decrease acute pain levels in dental procedures.

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
03/19/2025
Course expires: 
03/18/2028
Part of: 
Colorado Consortium for Prescription Drug Abuse Prevention
Rating: 
0

Don Teater is a board-certified family physician who has practiced medicine for over 30 years. Since 2013 he has focused mostly on the treatment of pain and addiction. From 2013 to mid-2016, he worked as the Medical Advisor at the National Safety Council addressing the national epidemic of opioid abuse, addiction, and overdose. Dr. Teater was lead facilitator for the expert panel during the development of the CDC Guideline for Prescribing Opioids for Chronic Pain 2016. He continues to work as a consultant with federal and state organizations. He also educates prescribers nationally on the appropriate treatment of pain and opioid use disorder. Don continues to see patients one day a week treating the disease of addiction via telemedicine from his home in Denver, CO to his patients in North Carolina. He is also a pain and addiction specialist for Southeast Alaska Regional Health Consortium in Juneau where he sees patients one week each month.

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Compass Healthcare Collaborative and Colorado Consortium for Prescription Drug Abuse Prevention. Compass Healthcare Collaborative is accredited by the IMS to provide continuing medical education for physicians.

Designation: Compass designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support: This activity was developed without support from any ineligible company. *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: Compass adheres to the Standards for Integrity and Independence in Accredited Continuing Education. The content of this activity is not related to products or the business lines of an ACCME-defined ineligible company. None of the planners or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
Please login or register to take this course.